Loading…
AstraZeneca PLC is projected to rise to $192.30 by 2027, a +12% move from its current price of $171.61. AZN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $168.17 | $171.61 | $175.11 | 0.00% |
| Jul 14 | $166.77 | $171.60 | $176.57 | -0.01% |
| Jul 15 | $165.69 | $171.60 | $177.71 | -0.01% |
| Jul 16 | $164.79 | $171.59 | $178.67 | -0.01% |
| Jul 17 | $164.01 | $171.59 | $179.52 | -0.01% |
| Jul 18 | $163.30 | $171.58 | $180.29 | -0.02% |
| Jul 19 | $162.64 | $171.58 | $181.00 | -0.02% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $162.64 | $171.58 | $181.00 | -0.02% |
| Week 2 | $159.05 | $171.54 | $185.01 | -0.04% |
| Week 3 | $156.34 | $171.51 | $188.15 | -0.06% |
| Week 4 | $154.09 | $171.47 | $190.82 | -0.08% |
| Week 5 | $152.12 | $171.44 | $193.21 | -0.10% |
| Week 6 | $150.37 | $171.41 | $195.39 | -0.12% |
| Week 7 | $148.77 | $171.37 | $197.41 | -0.14% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI.
It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia.
It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999.
AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
AstraZeneca PLC (AZN) is currently priced at $171.61 with a market cap of $266.15B and a rank of 54. The current price and market position place it among large-cap, globally recognized pharmaceutical players.
Near-term forecasts show a mixed but evolving path, with 2026’s average price at $171.61 and 2027 at $192.30, followed by 2028 at $196.48 and 2029 at $210.71. The multi-year outlook turns progressively more bullish, with 2030 averaging $259.12 and 2040 averaging $494.02, culminating in 2050 averaging $1,013.68 and a max of $1,692.32. These figures illustrate substantial upside potential over the long arc while highlighting near-term uncertainty.
A major floor 9.1% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 13.7% above — a clean break opens room to run.
A major ceiling 19.5% above — clearing it would confirm fresh momentum.
Key AZN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AZN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $184.53 | Sell | $181.42 | Sell |
| MA 10 | $187.06 | Sell | $183.92 | Sell |
| MA 20 | $183.33 | Sell | $184.17 | Sell |
| MA 50 | $183.63 | Sell | $185.25 | Sell |
| MA 100 | $190.52 | Sell | $186.06 | Sell |
| MA 200 | $184.24 | Sell | $181.28 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 38.38 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -138.93 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.82 | Sell |
| ROC (12) | -5.20 | Sell |
| Bollinger %B (20,2) | 0.05 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.06 | Buy |
| Awesome (5,34) | 1.23 | Buy |
| Ultimate (7,14,28) | 37.26 | Neutral |
| Momentum (10) | -14.07 | Sell |
| Aroon Osc (25) | -20.00 | Sell |
| Hull MA (9) | 180.23 | Sell |
| ADX (14) | 14.52 | Neutral |
| ATR (14) | 4.18 | Info |
The 30-day technical picture is bearish at the moment. RSI14 is 40, indicating modest negative momentum.
The short-term moving averages show a SMA50 of $183.63 and a SMA200 of $184.24, suggesting the price is hovering around key long-term levels. Near-term support sits at $171.61, with resistance at $195.15. The 30-day range spans from $150.21 to $196.06, highlighting a wide price fluctuation window over the month.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $171.61 | $171.61 | $215.40 | 0% | Neutral | |
| $156.78 | $192.30 | $247.12 | +12% | Neutral | |
| $157.00 | $196.48 | $259.76 | +14% | Neutral | |
| $165.62 | $210.71 | $284.89 | +23% | Bullish | |
| $200.73 | $259.12 | $357.03 | +51% | Bullish | |
| $217.14 | $284.00 | $397.87 | +65% | Bullish | |
| $228.24 | $302.17 | $429.71 | +76% | Bullish | |
| $240.54 | $322.09 | $464.32 | +88% | Bullish | |
| $237.52 | $321.47 | $469.29 | +87% | Bullish | |
| $258.86 | $353.96 | $522.80 | +106% | Bullish | |
| $345.11 | $494.02 | $766.63 | +188% | Bullish | |
| $655.96 | $1,013.68 | $1,692.32 | +491% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $171.61 | $171.61 | $199.66 | +0.00% |
| August 2026 | $143.47 | $168.19 | $201.62 | -1.99% |
| September 2026 | $145.27 | $171.17 | $206.89 | +1.77% |
| October 2026 | $144.08 | $170.51 | $207.55 | -0.38% |
| November 2026 | $143.01 | $169.87 | $207.99 | -0.38% |
| December 2026 | $146.79 | $174.98 | $215.40 | +3.00% |
Click any year to see its month-by-month AZN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, AZN could reach as high as $215.40, with a base case around $171.61 and support toward $171.61 — roughly 0% from $171.61. Price action looks broadly range-bound.
Expect AZN to range from $156.78 to $247.12 through 2027. The $192.30 average target implies a +12% move from current prices. That is up +12% on the projected 2026 average. A consolidation phase looks the most probable path here.
The AZN price prediction for 2028 points to an average of $196.48 (low $157.00, high $259.76) — a potential gain of +14% on today's $171.61. Price action looks broadly range-bound.
In 2029, AZN is projected to trade between $165.62 and $284.89, averaging $210.71 — a potential gain of +23% from today's $171.61. That is up +7% on the projected 2028 average. Buyers look set to stay in control over this stretch.
AstraZeneca PLC's 2030 outlook centres on $259.12, within a $200.73 to $357.03 range. That is up +23% on the projected 2029 average. That marks a +51% change versus current levels. Momentum favours further upside here.
By 2031, AZN could reach as high as $397.87, with a base case around $284.00 and support toward $217.14 — roughly +65% from $171.61. Buyers look set to stay in control over this stretch.
Expect AZN to range from $228.24 to $429.71 through 2032. The $302.17 average target implies a +76% move from current prices. That is up +6% on the projected 2031 average. Momentum favours further upside here.
The AZN price prediction for 2033 points to an average of $322.09 (low $240.54, high $464.32) — a potential gain of +88% on today's $171.61. Buyers look set to stay in control over this stretch.
In 2034, AZN is projected to trade between $237.52 and $469.29, averaging $321.47 — a potential gain of +87% from today's $171.61. That is 0% versus the projected 2033 average. Momentum favours further upside here.
AstraZeneca PLC's 2035 outlook centres on $353.96, within a $258.86 to $522.80 range. That is up +10% on the projected 2034 average. That marks a +106% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, AZN could reach as high as $766.63, with a base case around $494.02 and support toward $345.11 — roughly +188% from $171.61. Momentum favours further upside here.
Expect AZN to range from $655.96 to $1,692.32 through 2050. The $1,013.68 average target implies a +491% move from current prices. That is up +105% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in AZN today (≈ 5.827166 AZN) could be worth
$5,906.91
+$4,906.91 (+491%) by 2050 · US Dollar
Based on the average projected AZN price of $1,013.68 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AZNwould be worth at today's price.
$1,000 invested in AZN on Jul 10, 2025 (≈ 6.962819 AZN) would be worth
$1,194.89
+$194.89 (+19.5%) today · 1.19× · US Dollar
Based on a AZN entry price of $143.62 vs. today's $171.61.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $195.15 | $879.37 | -12.1% |
| 1 month ago | $178.96 | $958.93 | -4.1% |
| 3 months ago | $204.03 | $841.1 | -15.9% |
| 6 months ago | $187.26 | $916.43 | -8.4% |
| 1 year ago | $143.62 | $1,194.89 | +19.5% |
| All time (5.0y) ago | $121.22 | $1,415.69 | +41.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AZN forecast.
Our base-case forecast reaches $340.00 around 2035.
Implied market cap at $340.00: $527.3B
The multi-year forecast points to a bullish trajectory after a cautious start. By 2026, the min and avg are both $171.61 with a max of $215.40 and a neutral sentiment. From 2027 onward, the avg climbs to $192.30 (ROI 12.1%), 2028 to $196.48 (ROI 14.5%), and 2029 to $210.71 (ROI 22.8%), with a bullish tilt beginning to take hold by the end of the decade.
Looking further out, 2030 shows an avg of $259.12 with a 51% ROI and a bullish sentiment; 2040 shows an avg of $494.02 with an 187.9% ROI; and 2050 shows an avg of $1,013.68 with a 490.7% ROI and a max of $1,692.32. These figures reflect a sustained, long-term upside despite near-term volatility. Investors should note that these are estimates, not guarantees, and carry inherent uncertainty.
Tap a question to reveal the answer.
The forecast for 2030 shows avg $259.12, with a min of $200.73 and a max of $357.03; ROI 51; sentiment BULLISH.
Forecasts show rising averages from 2027 onward and a bullish stance from 2029, with ROI reaching 51% in 2030 and 490.7% by 2050; however, 2026 is neutral and there is risk and uncertainty in all forecasts.
Yes. The 2050 forecast shows avg $1,013.68 and max $1,692.32, with ROI 490.7%.
Current price is $171.61 and market cap is $266.15B; rank 54.
Bearish sentiment with RSI 14 at 40. The 30-day range is $150.21–$196.06, with support at $171.61 and resistance at $195.15.
AstraZeneca PLC Community Discussion
0Share your AstraZeneca PLC price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.